Emmis Acquisition (EMIS) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Emmis Acquisition is the larger company by market cap ($162.0 million vs $159.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | NKTX |
|---|---|---|
| Share price | $10.27 | $2.22 |
| Market cap | $162.02M | $159.01M |
| 1-day change | 0.00% | -2.20% |
| YTD return | +3.22% | +20.00% |
| 1-year return | — | +6.22% |
| 5-year return | — | -87.90% |
| EPS (TTM) | — | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.27 | $3.72 |
| 52-week low | $9.90 | $1.70 |
| Distance from 52-week high | 0.00% | -40.32% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +387.84% |
| Average volume | 13.67K | 617.86K |
| Shares outstanding | 11.94M | 71.62M |
| Employees | — | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
EMIS vs NKTX FAQ
Which is bigger, Emmis Acquisition or Nkarta?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $162.02M compared with $159.01M for Nkarta (NKTX).
Are Emmis Acquisition and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.